Perceptive Advisors LLC Sells 128,806 Shares of Palvella Therapeutics, Inc. $PVLA

Perceptive Advisors LLC lowered its stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 32.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 266,287 shares of the company’s stock after selling 128,806 shares during the quarter. Perceptive Advisors LLC owned 2.25% of Palvella Therapeutics worth $27,872,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PVLA. Millennium Management LLC bought a new stake in Palvella Therapeutics in the first quarter valued at approximately $7,553,000. Goldman Sachs Group Inc. purchased a new position in shares of Palvella Therapeutics during the first quarter valued at approximately $533,000. Geode Capital Management LLC increased its stake in shares of Palvella Therapeutics by 84.7% during the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after buying an additional 79,787 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, Rhumbline Advisers purchased a new position in shares of Palvella Therapeutics during the second quarter valued at approximately $224,000. Institutional investors own 40.11% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. Mizuho boosted their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Stephens reissued an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. HC Wainwright boosted their target price on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Chardan Capital reissued a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.53.

Palvella Therapeutics Stock Up 2.3%

Shares of PVLA stock opened at $112.63 on Thursday. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -27.01 and a beta of -0.15. The business’s fifty day moving average is $118.97 and its 200 day moving average is $108.85. Palvella Therapeutics, Inc. has a twelve month low of $20.20 and a twelve month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Equities research analysts expect that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.